Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3295668 Erbumine · 3 trials · 3 indications
Number of Participants with DLTs
ORR
DoR
Part II: Number of Participants with DLTs
ORR: Percentage of participants who achieve CR or PR
PK: AUC of LY3295668 Erbumine
| Arm | Type | Description |
|---|---|---|
| LY3295668 Erbumine Escalation | EXPERIMENTAL | LY3295668 Erbumine given orally. |
| LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation | EXPERIMENTAL | LY3295668 Erbumine given orally and topotecan and cyclophosphamide given intravenously (IV). |
| LY3295668 Erbumine Expansion | EXPERIMENTAL | LY3295668 Erbumine given orally. |
| LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion | EXPERIMENTAL | LY3295668 Erbumine given orally and topotecan and cyclophosphamide given IV. |
| LY3295668 Erbumine Part A | EXPERIMENTAL | LY3295668 erbumine administered orally (Part I). Approximately the first 10 participants enrolled in this arm will be administered midazolam. |
| LY3295668 Erbumine Part B | EXPERIMENTAL | LY3295668 erbumine administered orally (Part I). Approximately the first 10 participants enrolled in this arm will be administered midazolam. |
| LY3295668 Erbumine + Endocrine Therapy Cohort 1 | EXPERIMENTAL | LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part II). |
| LY3295668 Erbumine + Endocrine Therapy Continuation Part C | EXPERIMENTAL | LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I). |
| LY3295668 Erbumine + Endocrine Therapy Switch Part D | EXPERIMENTAL | LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I). |
| LY3295668 Erbumine Cohort A | EXPERIMENTAL | LY3295668 erbumine administered orally. |
| LY3295668 Erbumine Cohort B | EXPERIMENTAL | LY3295668 erbumine administered orally. |
| LY3295668 Part JP | EXPERIMENTAL | LY3295668 erbumine administered orally. |
| Name | Type | Description |
|---|---|---|
| LY3295668 Erbumine | DRUG | Administered orally. |
| Topotecan | DRUG | Administered IV. |
| Cyclophosphamide | DRUG | Administered IV. |
| Endocrine therapy | DRUG | Administered according to label instructions. |
| Midazolam | DRUG | Administered orally. |
Inclusion Criteria: * Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue. * Participants must be able to swallow capsules. Exclusion Criteria: * P...
Top 20 of 92 competitors
LY3295668 Erbumine is an investigational small molecule being studied for the treatment of metastatic breast cancer, neuroblastoma, and small cell lung cancer. It is in Phase 1 clinical development for these oncology indications.
LY3295668 Erbumine is being developed by Eli Lilly and Company, which trades under the ticker symbol LLY on the stock exchange.
LY3295668 Erbumine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing or completed to evaluate its safety and efficacy.
LY3295668 Erbumine has been studied in three Phase 1 trials: NCT03898791 in extensive-stage small-cell lung cancer, NCT03955939 in metastatic breast cancer, and NCT04106219 in relapsed/refractory neuroblastoma. These trials are completed or active but not recruiting.
LY3295668 Erbumine is the specific drug name used in clinical trials. No alternative names have been reported for this compound in the available clinical trial information.